Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in Idiopathic Pulmonary Fibrosis
NCT00391443Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2007
- Primary completion
- Feb 2010
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Bosentan with Placebo (2 arms). Primary endpoint: Time to Occurrence of Disease Worsening or Death up to End of Study at 36 months. Started Feb 2007; status: completed.
02
Drugs
bosentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00391443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391443.